Granules India Ltd

- There is no indication of any new fundraising through debt or equity in the call. - The company plans capex of around INR 600 crores for FY25, primarily for Granules Life Sciences expansion and other projects. - Net debt as of year-end is INR 842 crores, with a targeted net debt-to-EBITDA ratio of around 1 to 1.1, which the company aims to maintain rather than drastically reduce. - No plans to bring net debt down drastically; small fluctuations plus or minus may occur. - The company intends to maintain healthy net debt levels and is cautious about taking on more debt to keep the ratio within target. - Interest costs are expected to remain steady in the near term due to Fed rates. - Overall, no new fundraising announcements or plans were shared in the discussion.

- FY25 Capex estimated at INR 600 crores (INR 6,000 million). - Half of the capex allocated to Granules Life Sciences expansion; remaining for other projects and maintenance. - New formulation facility at Genome Valley (Granules Life Sciences) commenced operations in March 2024 with ramp-up expected to reach 100 million dosages per month by July-August 2024. - Granules Life Sciences capacity expected to generate INR 4-5 billion revenue in FY25. - Cautious approach to CZRO investment; spending aligned with project milestones ("state gate" approvals). - Commercial scale-up planned for the DCDA pilot plant at Kakinada following successful pilot operations in March 2024. - Strategic capex focused on backward integration of paracetamol and metformin in a sustainable manner (green pharma initiative). - Emphasis on expanding manufacturing technology platform and validation of new molecules by Q3 FY25 to achieve cost leadership and sustainability.

- Finished Dosage (FD) segment will be the main driver of future growth with healthy, possibly better than last year's growth. - New product launches, including CNS, ADHD, MUPS, and first-to-file launches, will significantly contribute to revenue growth starting FY25 and more markedly in FY26. - Value-added products expected to increase from 65% to around 70% of sales by next year, enhancing margins and revenue quality. - Formulation capacity ramp-up at Genome Valley expected to touch annualized revenue capacity of INR 4-5 billion by FY25. - New products anticipated to contribute 7-10% to FY25 revenues, with growth accelerating in subsequent years. - Market expansion, including increasing presence in U.S., Europe, and other regulated markets, supports volume and sales growth. - Despite challenges in Paracetamol API segment, stabilization expected from FY26 and overall good demand environment for most products.

- Finished Dosage (FD) segment expected to drive strong growth, possibly better than FY24's >25% growth. - EBITDA margin targeted around 22%-23%, with potential to maintain or improve; conservative outlook given. - Gross margins expected to sustain between 55%-58% driven by higher FD sales and favorable raw material costs. - New product launches anticipated to contribute 7%-10% of revenues in FY25, with growth in new products accelerating in subsequent years. - Capex of around INR600 crores planned in FY25 for expansions and maintenance, supporting future growth. - Demand environment broadly buoyant except paracetamol API, where stabilization expected by FY26. - R&D spends to continue or slightly increase due to strong pipeline, focusing on first-to-file and specialty segments like oncology. - Operating leverage expected as current higher costs (manpower, R&D) normalize with scaling revenues. - Net debt target maintained at a comfortable net debt to EBITDA ratio of 1.0-1.1.

- Granules India Limited, combining both GPI and GIL entities, currently has around 13 ANDAs (Abbreviated New Drug Applications) pending approval. - The company has a strong pipeline with many first-to-file launches, including oncology and other specialized areas. - They anticipate continuing R&D spend to support this pipeline and product development. - The company expects approximately 16 to 18 product launches in the fiscal year, of which 14 are new products and the rest product extensions/ramp-ups. - New product approvals, especially in CNS, ADHD, and MUPS categories, are expected to contribute significantly but not heavily from Q1 FY25. - Commercialization of oncology and other innovative products is planned to begin from FY26 onwards. - Capex of about INR 600 crores is planned for FY25, supporting expansion and other projects to meet order demands.